USPTO serial 79007265
TOCUDIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 23, 2006
- Examiner
- PINO, BRIAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TOCUDIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
NANNING MAPLE LEAF PHARMACEUTICAL CO. LTD.
CN
Other trademarks owned by NANNING MAPLE LEAF PHARMACEUTICAL CO. LTD.
NANNING MAPLE LEAF PHARMACEUTICAL CO. LTD.
CN
Other trademarks owned by NANNING MAPLE LEAF PHARMACEUTICAL CO. LTD.
NANNING MAPLE LEAF PHARMACEUTICAL CO. LTD.
CN
Other trademarks owned by NANNING MAPLE LEAF PHARMACEUTICAL CO. LTD.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joyce W. Jenzano
JOYCE W JENZANO MOORE & VAN ALLEN PLLC430 DAVIS DR STE 500MORRISVILLE, NC 27560UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Veterinary preparations and medicines for veterinary purposes, namely, anaesthetics and analgesics, for the treatment of pain, irritation from mechanical, chemical or ischemic stimulation and inflammation, and preparations for the treatment of withdrawal symptoms, and the treatment of drug dependency, and for abstaining from narcotics and other drugs; chemical preparations for veterinary purposes; chemical reagents for veterinary purposes; anaesthetics for surgical use, non surgical use, general, local and topical anaesthetics; syrups, namely, anaesthetic syrups, analgesic syrups, and syrups for the suppression of symptoms of drug withdrawal and for abstaining from narcotics and other drugs; chemico-pharmaceutical and pharmaceutical preparations, namely, anaesthetics and analgesics for the treatment of pain, or irritation from mechanical, chemical or ischemic stimulation, or inflammation, and for the treatment of withdrawal symptoms, the treatment of drug dependency, for abstaining from narcotics and other drugs, and for the treatment of pain or inflammation arising from cancer or cancer treatment; salts of biologically active organic compounds for medical purposes; gelatine based dosage forms containing pharmaceutical or chemico-pharmaceutical preparations or medicines for the treatment of pain and irritation and for the treatment of drug dependency and suppression of the symptoms of drug withdrawal; lozenges and pastilles for medical purposes, namely medicated lozenges, cough lozenges, throat lozenges, and lozenges and pastilles containing pharmaceutical or chemico-pharmaceutical preparations; medically prescribed or legally available synthetic narcotics; medically prescribed or legally available narcotics for the treatment of pain and irritation and for the treatment of drug dependency and suppression of the symptoms of drug withdrawal; ointments and lotions for pharmaceutical purposes, namely, anti-itch ointments, haemorrhoidal ointments, medicated rash ointments, ointments and lotions for the treatment of pain, irritation or discomfort; pectin containing preparations for pharmaceutical purposes, namely, anaesthetics and analgesics for the treatment of pain, irritation from mechanical, chemical or ischemic stimulation, or inflammation, and preparations for the treatment of withdrawal symptoms, the treatment of drug dependency, for abstaining from narcotics and other drugs, and for the treatment of pain or inflammation arising from cancer or cancer treatment; pills for pharmaceutical purposes, namely for the administration of pharmaceutical and chemico-pharmaceutical preparations in the nature of anaesthetics, analgesics and anti-irritant drugs, and preparations for the treatment of pain and drug dependency; poisons namely biological toxins or synthetic analogues or derivatives thereof for the treatment or amelioration of medical conditions, pain, irritation or discomfort, and for abstaining from drug dependency; sedatives; suppositories; medicines for human purposes, namely, anaesthetics and analgesics, for the treatment of pain, irritation from mechanical, chemical or ischemic stimulation and inflammation, and preparations for the treatment of withdrawal symptoms, the treatment of drug dependency, for abstaining from narcotics and other drugs, and for the treatment of pain or inflammation arising from cancer or cancer treatment; biological preparations for medical purposes; chemical preparations for pharmaceutical purposes; gases for medical purposes; chemical preparations for medical purposes; chemical reagents for medical purposes | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NANNING MAPLE LEAF PHARMACEUTICAL CO. LTD.
- Other trademarks owned by NANNING MAPLE LEAF PHARMACEUTICAL CO. LTD.
- Other trademarks owned by NANNING MAPLE LEAF PHARMACEUTICAL CO. LTD.
- Other trademarks in Class 005
- Similar marks named TOCUDIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 1, 2015 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Apr 10, 2015 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Apr 9, 2015 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Apr 9, 2015 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Aug 23, 2014 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Aug 23, 2014 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| May 6, 2014 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 6, 2013 | C71T | CANCELLED SECTION 71 | — |
| Dec 6, 2007 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 23, 2007 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 23, 2007 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 11, 2006 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 23, 2006 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 28, 2006 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 15, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 8, 2006 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 16, 2005 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Nov 21, 2005 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 18, 2005 | ALIE | ASSIGNED TO LIE | — |
| Nov 14, 2005 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 14, 2005 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 14, 2005 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 25, 2005 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 13, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 13, 2005 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 13, 2005 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 13, 2005 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 13, 2005 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 2, 2005 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 18, 2005 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 15, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 11, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 16, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 18, 2005 | NWAP | NEW APPLICATION ENTERED | — |
| Jan 13, 2005 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |